These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12928331)

  • 1. Parkin is recruited to the centrosome in response to inhibition of proteasomes.
    Zhao J; Ren Y; Jiang Q; Feng J
    J Cell Sci; 2003 Oct; 116(Pt 19):4011-9. PubMed ID: 12928331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.
    Ardley HC; Scott GB; Rose SA; Tan NG; Markham AF; Robinson PA
    Mol Biol Cell; 2003 Nov; 14(11):4541-56. PubMed ID: 12937272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation.
    Ren Y; Zhao J; Feng J
    J Neurosci; 2003 Apr; 23(8):3316-24. PubMed ID: 12716939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome.
    Jiang Q; Ren Y; Feng J
    J Neurosci; 2008 Nov; 28(48):12993-3002. PubMed ID: 19036992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
    Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
    J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease.
    Elkon H; Melamed E; Offen D
    Cell Mol Neurobiol; 2001 Dec; 21(6):771-81. PubMed ID: 12043847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates.
    Gu WJ; Corti O; Araujo F; Hampe C; Jacquier S; Lücking CB; Abbas N; Duyckaerts C; Rooney T; Pradier L; Ruberg M; Brice A
    Neurobiol Dis; 2003 Dec; 14(3):357-64. PubMed ID: 14678753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function.
    Tsai YC; Fishman PS; Thakor NV; Oyler GA
    J Biol Chem; 2003 Jun; 278(24):22044-55. PubMed ID: 12676955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkin is metabolized by the ubiquitin/proteosome system.
    Choi P; Ostrerova-Golts N; Sparkman D; Cochran E; Lee JM; Wolozin B
    Neuroreport; 2000 Aug; 11(12):2635-8. PubMed ID: 10976934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment.
    Mittal S; Dubey D; Yamakawa K; Ganesh S
    Hum Mol Genet; 2007 Apr; 16(7):753-62. PubMed ID: 17337485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitinylation and proteasome-dependent degradation of the phosphoinositide-specific phospholipase C gamma 1 in A-431 cells.
    Evdonin AL; Tsupkina NV; Nikol'skii NN; Medvedeva ND
    Dokl Biol Sci; 2003; 392():456-7. PubMed ID: 14650885
    [No Abstract]   [Full Text] [Related]  

  • 12. The degradation of nascent fibrinogen chains is mediated by the ubiquitin proteasome pathway.
    Xia H; Redman C
    Biochem Biophys Res Commun; 1999 Aug; 261(3):590-7. PubMed ID: 10441471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons.
    Petrucelli L; O'Farrell C; Lockhart PJ; Baptista M; Kehoe K; Vink L; Choi P; Wolozin B; Farrer M; Hardy J; Cookson MR
    Neuron; 2002 Dec; 36(6):1007-19. PubMed ID: 12495618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent ISG15 conjugation positively regulates the ubiquitin E3 ligase activity of parkin.
    Im E; Yoo L; Hyun M; Shin WH; Chung KC
    Open Biol; 2016 Aug; 6(8):. PubMed ID: 27534820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies.
    Longva KE; Blystad FD; Stang E; Larsen AM; Johannessen LE; Madshus IH
    J Cell Biol; 2002 Mar; 156(5):843-54. PubMed ID: 11864992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potential proteasome-interacting motif within the ubiquitin-like domain of parkin and other proteins.
    Upadhya SC; Hegde AN
    Trends Biochem Sci; 2003 Jun; 28(6):280-3. PubMed ID: 12826399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkin attenuates manganese-induced dopaminergic cell death.
    Higashi Y; Asanuma M; Miyazaki I; Hattori N; Mizuno Y; Ogawa N
    J Neurochem; 2004 Jun; 89(6):1490-7. PubMed ID: 15189352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response.
    Mimnaugh EG; Chen HY; Davie JR; Celis JE; Neckers L
    Biochemistry; 1997 Nov; 36(47):14418-29. PubMed ID: 9398160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactacystin, proteasome function, and cell fate.
    Fenteany G; Schreiber SL
    J Biol Chem; 1998 Apr; 273(15):8545-8. PubMed ID: 9535824
    [No Abstract]   [Full Text] [Related]  

  • 20. Degradation of the inducible cAMP early repressor (ICER) by the ubiquitin-proteasome pathway.
    Folco EJ; Koren G
    Biochem J; 1997 Nov; 328 ( Pt 1)(Pt 1):37-43. PubMed ID: 9359831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.